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Abstract
Background Vafidemstat, an inhibitor of the histone lysine-specific demethylase KDM1A, corrects cognition deficits and 
behavior alterations in rodent models. Here, we report the results from the first-in-human trial of vafidemstat in healthy young 
and older adult volunteers. A total of 110 volunteers participated: 87 were treated with vafidemstat and 23 with placebo.
Objectives The study aimed to determine the safety and tolerability of vafidemstat, to characterize its pharmacokinetic and 
pharmacodynamic profiles, to assess its central nervous system (CNS) exposure, and to acquire the necessary data to select 
the appropriate doses for long-term treatment of patients with CNS disease in phase II trials.
Methods This single-center, randomized, double-blind, placebo-controlled phase I trial included a single and 5-day repeated 
dose-escalation and open-label CNS penetration substudy. Primary outcomes were safety and tolerability; secondary out-
comes included analysis of the pharmacokinetics and pharmacodynamics, including chemoprobe-based immune analysis 
of KDM1A target engagement (TE) in peripheral blood mononuclear cells (PBMCs) and platelet monoamine oxidase B 
(MAOB) inhibition. CNS and cognitive function were also evaluated.
Results No severe adverse events (AEs) were reported in the dose-escalation stage. AEs were reported at all dose levels; 
none were dose dependent, and no significant differences were observed between active treatment and placebo. Biochemistry, 
urinalysis, vital signs, electrocardiogram, and hematology did not change significantly with dose escalation, with the excep-
tion of a transient reduction of platelet counts in an extra dose level incorporated for that purpose. Vafidemstat exhibits rapid 
oral absorption, approximate dose-proportional exposures, and moderate systemic accumulation after 5 days of treatment. 
The cerebrospinal fluid-to-plasma unbound ratio demonstrated CNS penetration. Vafidemstat bound KDM1A in PBMCs 
in a dose-dependent manner. No MAOB inhibition was detected. Vafidemstat did not affect the CNS or cognitive function.
Conclusions Vafidemstat displayed good safety and tolerability. This phase I trial confirmed KDM1A TE and CNS penetra-
tion and permitted characterization of platelet dynamics and selection of phase IIa doses.
Trial registration EUDRACT No. 2015-003721-33, filed 30 October 2015.
Key Points 
Vafidemstat displays good safety and tolerability in the 
dose range 0.2–2.5 mg/day.
A chemoprobe-based assay revealed that vafidemstat 
effectively bound the KDM1A target in humans.
Vafidemstat displays central nervous system penetration.
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1 Introduction
The etiology of sporadic neurodegenerative disorders such as 
Alzheimer’s or Parkinson’s disease is currently unknown. Epi-
genetics plays an important role in brain development and the 
establishment and loss of memory and cognition [1–4]; modu-
lation of epigenetic factors may present a unique opportunity 
for treatment of central nervous system (CNS) diseases [5].
KDM1A is a histone demethylase that has been proposed 
as a target for the treatment of neurodegenerative or neurode-
velopmental diseases [6–8].
Vafidemstat (ORY-2001) is an orally bioavailable and 
brain penetrant compound that was originally identified as 
a dual inhibitor of the flavin adenine dinucleotide (FAD)-
dependent amine oxidases KDM1A (EC 1.14.99.66) and 
monoamine oxidase B (MAOB; EC 1.4.3.4) [10]. KDM1A 
is a histone demethylase that acts in the nucleus and is 
involved in transcription regulation [9]. MAOB is structur-
ally related but involved in dopamine metabolism and is a 
validated drug target in Parkinson’s disease.
In vitro, vafidemstat inhibits the catalytic activity of 
KDM1A and MAOB through irreversible binding to their 
FAD cofactors. Vafidemstat also interferes with the capacity 
of KDM1A to interact with part of its recruiting transcription 
factors. In vivo, it primarily inhibits KDM1A, and MAOB 
inhibition is not significant in the therapeutic dose range. Vafi-
demstat restored cognition and behavior alterations in several 
rodent models [10]. Comparison of vafidemstat with selective 
KDM1A or MAOB inhibitors revealed that KDM1A inhibi-
tion is key to the efficacy of vafidemstat. In the brain, KDM1A 
is recruited by transcription factors, including serum response 
factor, and is involved in behavior alterations; vafidemstat pro-
motes the response of immediate early genes [10]. Vafidem-
stat also has anti-inflammatory activity in the CNS, evidenced 
by its efficacy in mouse models for multiple sclerosis (MS) 
[11]. In rodents, the therapeutic effects of vafidemstat can 
be achieved in the absence of an impact on hematopoiesis, a 
known on-target effect of KDM1A inhibition [12, 13].
Here, we report the results of a first-in-human phase I clini-
cal trial in healthy young and older adult volunteers. The study 
aimed to determine the safety and tolerability of vafidemstat, to 
characterize its pharmacokinetic and pharmacodynamic param-
eters, and to assess its CNS exposure. The data obtained from 
this study were used to select the appropriate doses for long-
term treatment of patients with CNS disease in phase II trials.
2  Materials and Methods
2.1  Study Drug and Treatment
The investigational medicinal drug substance and drug 
product (placebo or vafidemstat 0.2, 1, 1.5, or 4 mg in 
hydroxypropyl methylcellulose capsules) were manufactured 
in accordance with good manufacturing practices (GMP) 
guidelines and labeled according to Annex 13 of the EU 
GMP guidelines. The chemical structure of the compound 
is shown in Fig. 1a. The maximum recommended starting 
dose (MRSD) was 0.2 mg, as calculated in the most sensitive 
species (rat). The dose-escalation regimens were 0.2, 0.6, 
1.5, 2.5, and 4 mg for the single ascending dose (SAD) study 
and 0.2, 0.6, 1, 1.5, 2.5 mg, and an additional dose level of 
4.0 mg for the multiple ascending dose (MAD) study. In the 
cerebrospinal fluid (CSF) substudy, the doses were 2 and 4 
mg (Fig. 1c, d). Blinding, randomization, and dose-escala-
tion procedures are available in Supplemental Materials and 
Methods in Online Resource.
2.2  Study Design
This study was designed as a single-center, randomized, 
double-blind, placebo-controlled phase I trial to assess the 
safety, tolerability, pharmacokinetics, and pharmacody-
namics of vafidemstat. It consisted of a SAD study in male 
volunteers, a MAD study in healthy young and older adult 
populations, and a substudy of CSF.
The primary objectives of the study were to assess the 
safety and tolerability of vafidemstat; the secondary objec-
tives were to assess the pharmacokinetic and pharmacody-
namic profiles of vafidemstat after (1) single ascending oral 
dose administration in healthy young male volunteers, (2) 
repeated (5 days) ascending daily oral dose administration in 
young male and female healthy subjects, and (3) repeated (5 
days) daily oral dose administration in older adults.
The MRSD was determined according to US FDA and 
European Medicines Agency guidelines [14, 15] based on 
available preclinical data. The no observed adverse effect 
level (NOAEL) in nonclinical good laboratory practices 
Fig. 1  Clinical trial design. a Chemical structure of vafidemstat. 
b Impact of vafidemstat on platelet levels in nonclinical species, rep-
resented as % inhibition compared with control animals. All values 
are expressed as mg/m2/day to allow for direct comparison. Differ-
ences in administration (once daily by oral gavage in rats and dogs vs. 
drinking water in mice) were accounted for. Doses in mg/kg/day were 
converted to mg/m2/day by multiplication with the Km factor for each 
species (3, 6, 20, 37 for mouse, rat, dog, human, respectively). Black 
triangles indicate the SAMP8 efficacy studies in mouse; gray circles 
indicate the 28-day toxicity in rats; white squares indicate the 28-day 
toxicity in dogs; black arrows represent the doses chosen for the SAD 
and MAD cohorts; gray arrows represent those for the CSF cohorts 
in the phase I trial. The maximum recommended starting dose was 
0.2 mg. c Clinical trial doses per cohort. d Study design of the SAD, 
MAD, and CSF cohorts. Dark gray rectangle indicates the sentinel 
subject, light gray rectangles indicate subjects in active treatment; 
white rectangles indicate subjects receiving placebo. CSF cerebrospi-
nal fluid, MAD multiple ascending dose, p.o. oral administration, PLT 
platelet, QD once daily, SAD single ascending dose
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(GLP) toxicology studies in rats and dogs was established 
at 0.200 and 0.075 mg/kg, respectively. The MRSD was cal-
culated based on the NOAEL in a 28-day GLP toxicity study 
in rats, the most sensitive species:
MRSD = 1/safety factor × Km, rat/Km, human × 
NOAELrat × human body weight = 0.2 mg, where the safety 
factor = 10; Km, rat = 6; Km, human = 37; NOAELrat = 
0.2 mg/kg; and human body weight = 60 kg.
The dose escalation was designed to commence from 
the MRSD and continue to the minimum intolerable dose 
(MID). The MID was defined as the dose at which a serious 
adverse event (SAE) occurs in one or more subjects and the 
causality is established as certainly, probably, or possibly 
related to the study drug; when > 50% of subjects experi-
ence a limiting grade 2 or higher AE after active treatment 
but not placebo; when > 50% of AEs occur in subjects under 
active treatment but not placebo; or (in view of the role of 
KDM1A in hematopoiesis) when a > 50% decrease in plate-
let levels from baseline or grade 1 or higher thrombocyto-
penia platelet values are found in at least > 50% of subjects 
under active treatment but not placebo.
The original dose escalation regimens designed were 0.2, 
0.6, 1.5, 2.5, and 4 mg for the SAD and 0.2, 0.6, 1, 1.5, and 
2.5 mg for the MAD. This dose range was based on the 
nonclinical toxicology and efficacy data, was equivalent to 
the therapeutic dose in preclinical species, and was designed 
to identify the onset of hematological engagement (Fig. 1b). 
An extra cohort at 4 mg was incorporated into the MAD 
study after protocol modification. In the CSF pharmacoki-
netic substudy, the doses were 2 and 4 mg (Fig. 1d).
The eligibility criteria and programmed interventions 
are presented in Tables S1 and Tables S2–S4 in ESM-2, 
respectively.
2.3  Study Population and Assessments
Healthy adult male (SAD) and male or female subjects 
(MAD) complying with the eligibility criteria as shown in 
Table S1 in ESM-2 were randomized and included in the 
study and dosed in the SAD, MAD, and CSF studies. Vafi-
demstat or placebo were administered as a single oral dose 
(SAD and CSF pharmacokinetics) or as a daily oral dose for 
5 consecutive days (MAD).
Physical examination included vital signs, AE checklist, 
electrocardiograph (ECG), and neurological evaluations: 
visual analogue scale (VAS), Leeds Sleep Evaluation Ques-
tionnaire (LSEQ), Wisconsin Card Sorting Test (WCST), 
and Sternberg test. Blood samples were obtained for safety 
laboratory tests (hematology, biochemistry, and urinalysis) 
and at baseline and preestablished timepoints (see Tables 
S2–S4 in ESM-2) after the first drug administration for 
pharmacokinetic analysis using a GMP-validated method 
and for pharmacodynamic analysis to assess KDM1A target 
engagement (TE) and platelet MAOB activity in the SAD 
and MAD studies. An open-label CSF pharmacokinetics 
study was included to assess the pharmacokinetic profile 
in the CNS after a single oral dose of vafidemstat. Details 
about the assessments, analytical methods, and statistics are 
available in ESM-1.
2.4  Analytical Methods
2.4.1  Pharmacokinetics
Plasma and CSF samples for pharmacokinetic analysis were 
obtained predose and at preestablished timepoints. Vafidem-
stat concentrations were determined in human plasma and 
CSF using a highly sensitive GLP-validated liquid chroma-
tography–tandem mass spectrometry method (lower limit 
of quantification 10 pg/mL for plasma and 50 pg/mL for 
CSF) with electron spray ionization in positive ion mode 
and deuterated vafidemstat as internal standard, developed 
at Laboratorios Echevarne, S.A, Spain. Liquid–liquid extrac-
tion with ethyl acetate was used for sample processing, and 
chromatography was run on a Venusil XBP C18 column, 
with 0.1% formic acid in water and acetonitrile as mobile 
phases A and B, respectively. Intra- and interday precision 
in the validation ranged between 0.57 and 9.75% for plasma 
and between 1.18 and 5.63% for CSF. Intra- and interday 
accuracy (bias) in the validation ranged between − 4.74 and 
9.50% of the nominal values for plasma and between − 8.39 
and 10.25% of the nominal values for CSF. Incurred sample 
reanalysis was conducted on study samples to confirm the 
reproducibility of the bioanalytic method. All the repeat and 
original samples (n = 244 distributed into six independent 
bioanalytical batches for plasma and n = 10 into two batches 
for CSF) were within 20% of the mean of the two values, 
meeting the preestablished acceptance criteria of 67% and 
therefore confirming the reproducibility of the assay. Sample 
analysis was GLP compliant, and pharmacokinetic param-
eters—including the dose normalized maximum (peak) 
concentration (Cmax), time to reach Cmax (tmax), and area 
under the plasma concentration–time curve (AUC)—were 
calculated by means of noncompartmental analysis using 
 WinNonlin® 2.1 software. Plasma-concentration-versus-time 
profiles are presented on linear or log-linear scale mean pro-
files ± standard error of the mean for each treatment.
2.4.2  Plasma Unbound Concentrations
Plasma unbound concentrations were calculated by cor-
recting the measured total concentrations with the plasma 
fraction unbound value of 0.029, which had been sepa-
rately assessed in vitro by equilibrium dialysis using the 
 HTDialysis® system at Advinus Therapeutics Ltd., India.
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2.4.3  KDM1A Target Engagement
For the evaluation of KDM1A TE (% of KDM1 bound to 
vafidemstat), a proprietary chemoprobe-based assay [16, 17] 
was used at Oryzon Genomics S.A., Spain. Briefly, blood 
samples were collected in EDTA (ethylenediaminetetraacetic 
acid) K2 tubes from healthy volunteers at baseline and pre-
specified timepoints. Peripheral blood mononuclear cells 
(PBMCs) were obtained by density gradient centrifugation 
in LeucoSep™ tubes. Cells were lysed in 1X cell lysis buffer 
(Cell Signaling; #9803) containing 1X Complete Mini, pro-
tease inhibitor cocktail tablets (ROCHE; # 11836153001) 
in the presence of 25 nM biotinylated KDM1A chemoprobe 
OG-881. The chemoprobe binds the free KDM1A (i.e., not 
occupied by vafidemstat) in the sample. This lysate was then 
used to perform a chemiluminescent KDM1A sandwich 
enzyme-linked immunosorbent assay (ELISA) (using anti-
KDM1A-coated ELISA plates) and a chemoprobe ELISA 
(using streptavidin-coated ELISA plates) to determine both 
total and free KDM1A in the sample. Streptavidin (Promega 
Biotech Ibérica; #Z7041) at 10 µg/mL in phosphate buff-
ered saline (PBS) or mouse monoclonal anti-KDM1A anti-
body (Abcam; #ab53269) at 2 µg/mL in PBS were used to 
coat LumiNunc Plates MaxiSorp (NUNC; #436110) plates. 
Rabbit monoclonal anti-KDM1A antibody (Cell Signal-
ing; #2184) at 0.125 µg/mL in PBS was used for primary 
detection, and the peroxidase-conjugated secondary anti-
rabbit immunoglobulin G antibody (Jackson ImmunoRe-
search; #711-035-152) at 1:5000 dilution in PBS was used 
for secondary detection in combination with 100 µL/well 
of chemiluminescent substrate (Invitrogen; #37074). Anti-
body #2184 recognizes the N-terminal and #ab53269 the 
C-terminal region of KDM1A in the native complex. The 
KDM1A antibodies used were KDM1A knockout validated, 
and we confirmed that coincubation with synthetic peptides 
corresponding to the respective target epitopes eliminated 
the KDM1A signal. Intraday precision of the validation 
in human PBMC ranged between 0.31 and 5.08% for total 
KDM1A and between 1.03 and 8.02% for free KDM1A. 
Interday precision was 11.9 and 19.7% for total and free 
KDM1A, respectively.
All ELISA and chemoprobe ELISA assays were run 
as technical triplicates. After raw data processing (robust 
elimination of outliers according to Grubbs criteria and sub-
traction of blank signal), the TE or percentage of KDM1A 
bound by vafidemstat was calculated relative to the predose 
sample (T0) from the same subject as follows:
where
3  Results
The first subject was enrolled on 4 April 2016, and the last 
subject completed the study on 2 June 2017. Subjects were 
screened during the 28 days prior to dosing.
A total of 40 healthy young male subjects were enrolled 
in the SAD study and treated with placebo or vafidemstat 
(randomization ratio 2:6) at doses ranging from 0.2 to 4 mg. 
Eight subjects were enrolled per dose level.
In the MAD study, 40 healthy young male and female 
subjects were enrolled and treated for 5 days with placebo 
or vafidemstat (randomization ratio 2:6) at doses ranging 
from 0.2 to 2.5 mg per day. Eight subjects were enrolled per 
each of the dose levels. After a protocol modification, four 
additional young subjects were enrolled in a sixth cohort 
and treated for 5 days with placebo or vafidemstat (rand-
omization ratio 1:3) at 4 mg per day. Finally, four older adult 
subjects were enrolled and treated for 5 days with placebo 
or vafidemstat at 2.5 mg per day (randomization ratio 1:3).
The demographics and baseline characteristics of the 
subjects are summarized in Table S5 in ESM-2. In the SAD 
and MAD studies, the distribution of demographics was 
similar in the treated and placebo arms. All subjects were 
Caucasian.
3.1  Safety and Tolerability
A total of 120 AEs were reported during the three study 
stages (SAD, MAD, and older adult population): 90 AEs 
by subjects receiving vafidemstat and 30 AEs by subjects 
receiving placebo, i.e., the same proportion as the treatment 
to placebo randomization (3:1). Of these, 108 AEs were 
classified as treatment-emergent AEs (TEAEs) possibly or 
probably related to the study drug: 79 TEAEs were reported 
in volunteers treated with vafidemstat and 29 in volunteers 
treated with placebo. No differences in the proportion of 
subjects reporting AEs or differences between the AEs 
reported were observed between the active treatment and 
placebo. No SAEs were reported during the study.
During the SAD stage in healthy young male volunteers 
(N = 40), 15 AEs were reported; 13 were considered to 
be treatment related (12 in subjects receiving vafidemstat 
and one in the placebo arm). Nine subjects experienced at 
least one AE. In the vafidemstat treatment group, the most 
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common AEs were headache, followed by euphoric mood. 
None of the AEs were dose dependent.
During the MAD stage in healthy young male/female 
volunteers (N = 44), a total of 69 AEs were reported (51 
AEs with vafidemstat and 18 with placebo). The most com-
mon AEs were headache, followed by dry mouth, asthenia, 
postural dizziness, and somnolence. In total, 61 AEs were 
related to the study treatment (44 with vafidemstat and 17 
with placebo). The data from a subcohort (N = 4) subject 
to a dosing error are represented separately in Table S6 in 
ESM-2. None of the AEs were considered severe. Moder-
ate AEs (all headaches experienced with vafidemstat) were 
reported in dose levels I (0.2 mg/day), III (1.0 mg/day), and 
IV (1.5 mg/day) but not in the highest dose levels (V and VI, 
2.5 and 4 mg/day, respectively). The rest of the AEs were 
considered mild. Regarding the AEs reported in the highest 
dose levels, the proportion of subjects who experienced the 
most common AEs was similar in the active treatment and 
placebo arms.
Safety and tolerability results from the MAD stage in 
young male and female volunteers supported the initiation 
of the MAD stage in older adult volunteers at dose level VI 
(4.0 mg/day, N = 4; three active and one placebo). A total 
of 23 AEs were reported: 12 with vafidemstat and 11 with 
placebo. Three subjects reported at least one AE. The most 
common AEs were postural dizziness (in a subject in the 
placebo arm) followed by headache, blunted affect, and ver-
tigo. Most reported AEs were mild. A total of 21 treatment-
related TEAEs were reported (10 with vafidemstat and 11 
with placebo). TEAEs possibly or probably related to the 
study drug in the SAD, MAD, and older adult cohort are 
presented in Table 1.
No significant changes were observed over time in hema-
tological, biochemical, or urinalysis parameters or in vital 
signs or ECG values in the planned SAD or MAD (including 
older adult) cohorts. Platelet levels showed no variations at 
any of the SAD dose levels or up to MAD dose III (1.0 mg/
day). At MAD dose levels IV (1.5 mg/day) and V (2.5 mg/
day), platelet counts were within the normal range, but a ten-
dency for lower counts was emerging in the active treatment 
arm compared with the placebo arm. At 1.5 and 2.5 mg/
day, a slight reduction (− 11 and − 21%) of the mean was 
observed by 192 h after the first administration and a small 
rebound (+ 15 and + 18%) was observed in the follow-up 
visit (Fig. 2a, b). Although the differences between placebo 
and active treatment arms were not significant, these changes 
were thought to reflect the first indication of hematopoietic 
engagement. A protocol amendment was issued to incor-
porate an additional MAD dose (level VI; N = 4; placebo 
or 4 mg/day) to characterize the hematopoietic impact. At 
this dose level, a transient reduction of platelet levels was 
observed by 192 h, and platelet evolution was monitored to 
characterize the nadir and rebound. Platelets dropped below 
50% of baseline levels in two of three vafidemstat-treated 
subjects by 216 h after the first treatment administration and 
in all subjects at 240 h and 264 h and recovered during the 
follow-up visits (Fig. 2c). Based on these data, the MID 
as defined per protocol was met at dose 4 mg/day, and the 
maximum tolerated dose was established at 2.5 mg/day.
In summary, no SAEs or AEs leading to treatment discon-
tinuation were reported in the SAD or MAD cohorts. With 
exception of the effect on platelets observed in the extra 
cohort (4 mg/day) as described, all hematology, biochemis-
try, and urinalysis parameters, as well as vital signs and ECG 
assessments in SAD and MAD, were within normal ranges 
in the vafidemstat treatment arms and revealed no significant 
differences between treatment arms.
3.2  Pharmacokinetics
In the SAD and MAD cohorts, the plasma pharmacokinetic 
profiles of vafidemstat after single (Fig. 3a) and multiple 
(Fig. 3b) dosing reflected rapid oral absorption, with a tmax 
of ~ 0.5–2 h, moderate variability (overall coefficient of 
variation ≤ 30%), a relatively long half-life (~ 20–30 h), 
and approximately dose-proportional exposures (based on 
dose normalized Cmax and AUC). A tendency for more than 
proportional increases was found starting from the dose of 
2.5 mg/day in the MAD cohort, which could result from a 
saturation of drug absorption and/or elimination at higher 
dose levels, among other causes. Apparent clearance was 
low (6 L/h). A moderate systemic accumulation (mean accu-
mulation ratios [AUC 0–t Day5/AUC 0–t Day1] ~ 2) was observed 
after 5 days of administration, and pharmacokinetic mod-
eling indicated that a stationary state would be reached 
between approximately days 5 and 7 (data not shown). 
Pharmacokinetic profiles at 2.5 mg/day did not differ sig-
nificantly between the young and older adult populations 
(Fig. 3b). The mean apparent volume of distribution was 
150 L, indicating potentially low to moderate distribution 
to tissues (Table 2).
In the CSF cohort, vafidemstat was shown to cross the 
human blood–brain barrier, with quantifiable concentra-
tions found from 2 h post-dose, the first timepoint analyzed. 
Additionally, CSF/plasma (unbound) ratios observed in this 
study (mean of 0.81) suggested that no or minor CNS-to-
blood efflux transport of vafidemstat is expected in humans 
(Fig. 3c and Table 2).
3.3  Pharmacodynamics
Failure to efficiently inhibit the target is a factor that con-
tributes to the low success rate of clinical drug development 
and underscores the relevance of demonstrating target occu-
pancy in early-stage clinical trials. To evaluate the pharma-
codynamics of vafidemstat, we used a chemoprobe-based 
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Table 1  Number of TEAEs (and percentage of total TEAEs) possibly or probably related to the study drug by preferred term and dose levels/(n 
= subjects) in the SAD, MAD, and older adult cohorts
Data are presented as n (%). AEs occurring on the same day are only counted once
AE adverse event, MAD multiple ascending dose, MedDRA Medical Dictionary for Regulatory Activities, SAD single ascending dose, TEAE 
treatment-emergent adverse event
Cohort and MedDRA AE term Placebo I (0.2 mg/day) II (0.6 mg/day) III (1.0 mg/day) III (1.5 mg/day) IV (2.5 mg/day) V (4.0 mg/day)
SAD cohort n = 10 n = 6 n = 6 n = 0 n = 6 n = 6 n = 6
Diarrhea 1 (7.7)
 Headache 1 (7.7) 1 (7.7) 1 (7.7)
 Feeling hot 1 (7.7)
 Euphoric mood 1 (7.7) 1 (7.7)
 Musculoskeletal stiffness 1 (7.7)
 Paresthesia 1 (7.7)
 Abdominal discomfort 1 (7.7)
 Dry mouth 1 (7.7)
 Asthenia 1 (7.7)
 Blunted affect 1 (7.7)
 Total 13 (100) 1 (7.7) 1 (7.7) 3 (23.1) 2 (15.4) 3 (23.1) 3 (23.1)
MAD cohort n = 11 n = 6 n = 6 n = 6 n = 6 n = 6 n = 3
 Palpitations 1 (1.6)
 Dry mouth 5 (8.2) 4 (6.5) 3 (4.9) 1 (1.6)
 Asthenia 2 (3.3) 2 (3.3) 1 (1.6) 1 (1.6)
 Feeling hot 1 (1.6) 1(1.6)
 Muscle spasms 1(1.6)
 Dizziness postural 2 (3.3) 1(1.6) 1 (1.6)
 Headache 3 (4.9) 3 (4.9) 1 (1.6) 2 (3.3) 2 (3.3) 2 (3.3)
 Dyspepsia 1 (1.6)
 Salivary hypersecretion 1 (1.6) 1 (1.6)
 Feeling drunk 1 (1.6)
 Somnolence 2 (3.3) 1 (1.6)
 Apathy 1 (1.6)
 Blunted affect 2 (3.3)
 Euphoric mood 1 (1.6)
 Daydreaming 1 (1.6)
 Diplopia 1 (1.6)
 Vision blurred 1 (1.6)
 Constipation 1 (1.6) 1 (1.6)
 Feeling cold 3 (4.9)
 Nasopharyngitis 1 (1.6)
 Hematoma 1 (1.6)
 Total 61 (100) 17 (27.9) 10 (16.4) 11 (18.0) 13 (21.3) 7 (11.5) 1 (1.6) 2 (3.3)
Elderly cohort n = 1 n = 3
 Palpitations 1 (4.8)
 Vertigo 1 (4.8) 1 (4.8)
 Diarrhea 2 (9.5)
 Asthenia 1 (4.8)
 Feeling cold 1 (4.8)
 Gait disturbance 1 (4.8)
 Musculoskeletal stiffness 1 (4.8)
 Postural dizziness 4 (19.0)
 Headache 3 (14.3)
 Somnolence 1 (4.8)
 Blunted effect 2 (9.5) 1 (4.8)
 Euphoric mood 1 (4.8)
 Total 21 (100) 11 (52.4) 10 (47.6)
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immunoassay [16, 17]. The assay was validated for use in 
clinical trials and used to calculate the TE from the amount 
of free (uninhibited) and total KDM1A protein in PBMC 
samples obtained predose and at different timepoints after 
administration (Fig. 4a, b). Vafidemstat bound KDM1A in 
PBMCs in a dose-dependent manner. In the SAD cohorts, a 
maximum KDM1A TE of around 80% was observed at 12 h 
(4 mg), and substantial binding remained 72 h after dosing 
(Fig. 4c). KDM1A TE values observed 12 h after the last 
dose in the MAD study (108 h after first dose) were similar 
to those found in the SAD study. Maximum TE values of 
up to 90% were reached at 108 h. KDM1A TE turnover was 
slow, with 40–60% TE remaining at 192 h (96 h after last 
dose, Fig. 4d). KDM1A TE increased with plasma expo-
sure, reaching a peak of ~ 90% at Cmax,ss (where ss is steady 
state) of ~ 30 ng/mL and AUCss of ~ 500 ng·h/mL. Thus, 
a clear relationship was evidenced between the Cmax/AUC 
parameters and the amount of vafidemstat bound to KDM1A 
in the tested dose range (Fig. 4e, f). Similarly, the impact 
on platelets increased with exposure, reaching level drops 
(from baseline) of ~ 50% at Cmax,ss of ~ 100 ng/mL and 
AUC ss of ~ 1000 ng·h/mL (Fig. 4g, h). KDM1A TE was 
85.6% in the older adult population (evaluable sample from 
a single individual), comparable with that observed in young 
volunteers at the same dose level. As far as we can tell, this 
is the first time a chemoprobe-based method has been used 
to effectively monitor the dynamics of TE in a clinical trial.
KDM1A TE in the brain could not be tested in this study 
because no KDM1A positron emission tomography tracer 
was available. However, since vafidemstat binds KDM1A in 
the human brain and PBMC samples ex vivo with compa-
rable efficacy (data not shown), and the calculated plasma 
Fig. 2  Hematological impact 
of vafidemstat. Impact of 
vafidemstat on platelet levels at 
a 1.5 mg/day, b 2.5 mg/day, and 
(c) the extra dose level of 4 mg/
day, represented as % change 
from baseline levels. Black dots 
indicate vafidemstat (volunteers 
analyzed n = 6 in [a/b] or n = 
3 in [c]); open circles indicate 
placebo treatment (volunteers 
analyzed n = 2 in [a/b] or n = 
1 in [c]); black arrows represent 
dosing occasions. Data are pre-
sented as means and standard 
error of the mean. CFB change 
from baseline
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unbound vafidemstat levels were similar to those in CSF, 
the available pharmacokinetic and pharmacodynamic data 
anticipate proper brain KDM1A TE.
Finally, vafidemstat did not significantly inhibit platelet 
MAOB levels in vivo in the dose range used (Fig. S1 in 
ESM-3).
3.4  Neuropsychological Assessments
Treatment with vafidemstat did not provoke somnolence 
or reveal a potential for abuse in the SAD, MAD, or CSF 
cohorts, as assessed using a VAS. Subjects reported feel-
ing “partially calm” throughout the study, a feeling shared 
by those receiving placebo or vafidemstat regardless of the 
dose level administered and attributed to participation in 
the study. Vafidemstat did not disrupt sleeping or awaken-
ing patterns, as assessed by the LSEQ in the SAD, MAD, or 
CSF cohorts. A few spurious individual VAS values com-
posing the global score reached statistical significance, but 
no dose response was observed. No significant differences 
were observed at any dose level or parameter in the WCST 
or Sternberg test in the SAD, MAD, or CSF cohorts.
Fig. 3  Vafidemstat pharmacokinetics. (a) Plasma concentrations 
after single and (b) multiple ascending doses in healthy young (full 
lines) and older adult (dotted line) subjects. Light blue circles 0.2 mg; 
white squares 0.6 mg; light blue triangles 1 mg; white triangles 1.5 
mg; blue diamonds 2.5 mg; white circles 4 mg. Data are presented 
as mean and standard error of the mean. Volunteers analyzed at each 
datapoint, n = 6 except for MAD 4 mg, n = 3. (c) Cerebrospinal fluid 
(full lines) and plasma (unbound, dotted lines) concentrations after a 
single dose of 2 mg (diamonds) or 4 mg (circles)
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Table 2  Pharmacokinetics and central nervous system penetrance of vafidemstat
Data are presented as mean (coefficient of variation, %)
a Plasma pharmacokinetic parameters of the SAD and MAD (after single [D1] and 5-day repeated [D5] dose) cohorts. n = 6 healthy young vol-
unteers per cohort (0.2–4 mg SAD and 0.2–2.5 mg/day MAD), n = 3 healthy young volunteers in the 4 mg/day MAD cohort, and n = 3 older 
healthy adult volunteers in the 2.5 mg/day cohort. MAD AUC inf (D1) not reported as extrapolated AUC was > 20%
b Pharmacokinetic parameters in the CSF cohort after administration of a single dose. CSF and  plasmau concentrations, and CSF-to-plasmau 
ratios after a single dose of vafidemstat 2 or 4 mg. n = 3 subjects per timepoint
AUC 0–inf area under the concentration–time curve within time 0 to infinity, AUC 0–t area under the concentration–time curve within time 0–24 
h, CL/F apparent clearance, Cmax maximum (peak) concentration, CSF cerebrospinal fluid, D1 day 1, D5 day 5, MAD multiple ascending dose, 
plasmau plasma unbound, RAC ratio of accumulation (calculated from t½/Ke; Ke elimination rate constant), SAD single ascending dose, ss steady 
state, t½ terminal half-life, tmax time to reach Cmax, Vd/F apparent volume of distribution
Cohort and param-
eter
Dose level and results
SADa I: 0.2 mg  
(n = 6)
II: 0.6 mg  
(n = 6)
III: 1.5 mg  
(n = 6)
IV: 2.5 mg  
(n = 6)
V: 4.0 mg  
(n = 3)
 tmax (h) 2.75 (59) 1.83 (36) 0.92 (56) 1.58 (83) 1.71 (73)
 Cmax (ng/mL) 1.11 (24) 3.21 (12) 11.95 (29) 18.78 (30) 38.05 (33)
 AUC 0–t (ng·h/mL) 28.03 (12) 83.32 (13) 297.12 (50) 402.09 (20) 550.01 (17)
 AUC 0–inf (ng·h/
mL)
30.93 (16) 90.67 (13) 427.58 (80) 438.11 (25) 568.46 (18)
 Vd/F (L) 260 (20) 256 (14) 213 (9.7) 203 (9.5) 204 (17)
 CL/F (L/h) 6.59 (14) 6.72 (14) 5.34 (52) 6.03 (26) 7.20 (15)
 t½ (h) 28 (28) 27 (6.6) 41 (76) 25 (28) 20 (17)
MADa I: 0.2 mg/day  
(n = 6)
II: 0.6 mg/day  
(n = 6)
III: 1.0 mg/day 
(n = 6)
IV: 1.5 mg/day 
(n = 6)
V: 2.5 mg/day  
(n = 6)
Older adult: 2.5 
mg/day (n = 6)
VI: 4.0 mg/day  
(n = 3)
 tmax, ss (h after 
last dosing)
5.1 (1.7) 2.25 (1.4) 1.83 (1.7) 1.17 (0.4) 2.17 (1.7) 2.33 (1.6) 1.33 (1.1)
 Cmax (ng/mL) 
(D1)
1.28 (23) 3.69 (22) 6.83 (56) 11.35 (30) 26.64 (54) 24.28 (12) 55.97 (27)
 Cmax,ss (ng/mL) 
(D5)
2.32 (17) 7.65 (39) 14.11 (43) 23.61 (18) 49.92 (59) 41.00 (42) 109.73 (50)
 AUC 0–t (ng·h/mL) 
(D1)
18.73 (21) 50.57 (28) 95.08 (35) 137.96 (17) 292.25 (45) 257.53 (33) 563.85 (28)
 AUC 0–t,ss (ng·h/
mL) (D5)
37.69 (18) 113.68 (49) 198.74 (38) 298.69 (17) 634.21 (65) 442.23 (39) 994.50 (49)
 RAC 1.91 (17) 1.90 (22) 1.92 (9.2) 1.87 (7.0) 1.86 (7.2) 1.92 (6.7) 1.79 (15)
 t½ (h) 22 (25) 22 (33) 23 (14) 22 (11) 22 (11) 23 (10) 20 (23)
CSFb 2.0 mg  
( n = 3)
4.0 mg  
( n = 3)
 CSF (pg/mL) 
@ 2 h
239.42 (56) 387.34 (41)
 CSF (pg/mL) 
@ 6 h
181.47 (11) 733.75 (27)
 CSF (pg/mL) @ 
12 h
169.68 (14) 549.93 (5.3)
  Plasmau (pg/mL) 
@ 2 h
315.68 (56) 589.71 (56)
  Plasmau (pg/mL) 
@ 6 h
248.31 (17) 870.66 (13)
  Plasmau (pg/mL) 
@ 12 h
186.35 (23) 609.11 (12)
 CSF/plasmau 
@ 2 h
0.78 (15) 0.69 (18)
 CSF/plasmau 
@ 6 h
0.74 (7.8) 0.83 (14)
 CSF/plasmau @ 
12 h
0.92 (8.9) 0.91 (15)
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4  Discussion
Inhibitors of KDM1A have attracted attention for their 
potential use in the treatment of oncological diseases such 
as acute myeloid leukemia and small-cell lung cancer. Com-
pounds currently undergoing clinical testing in oncology and 
hematology include iadademstat (ORY-1001) [18], bome-
demstat (IMG-7289) [19], CC-90011 [20], and INCB059872 
[21].
Vafidemstat (ORY-2001) is the first KDM1A inhibitor 
envisaged for CNS disease and evaluated in healthy vol-
unteers. This study reports the results of a first-in-human 
phase I clinical trial of vafidemstat in healthy young and 
older adult volunteers to determine its safety and tolerabil-
ity, to characterize its pharmacokinetics and pharmacody-
namics, and to assess its CNS exposure. Vafidemstat was 
well-tolerated and did not produce any SAEs in the SAD or 
MAD studies. AEs were mild to moderate, and none were 
dose related, and the total frequency of AEs was similar in 
subjects receiving vafidemstat or placebo.
The pharmacokinetic data from this phase I trial indi-
cate that vafidemstat is suitable for daily administration. 
The compound presents moderate accumulation after 5-day 
treatment, reaches steady state by day 5, and is CNS pen-
etrant. Whereas in vitro biochemical assays indicated near 
equipotency for KDM1A TE and MAOB inhibition, phar-
macodynamic analyses on ex vivo samples from healthy vol-
unteers revealed dose-dependent KDM1A TE in PBMCs but 
no platelet MAOB inhibition. These data correspond with 
previous ex vivo findings obtained in preclinical species 
that show vafidemstat acts primarily as a selective KDM1A 
inhibitor in  vivo, with no significant pharmacological 
MAOB activity at the therapeutic doses used. No signifi-
cant effects were detected on hematology in the SAD and 
MAD studies at the initially planned doses, and escalation 
in the MAD was continued until the expected hematological 
impact emerged. Platelet level was the only parameter that 
was significantly altered in this study, as expected and previ-
ously observed for other KDM1A inhibitors.
The obvious limitations of this first-in-human trial are 
the small number of subjects included in each dose level 
(especially in the older adult population), which may not 
reveal less frequent AEs, and the short treatment duration, 
which does not permit evaluation of long-term effects. Dif-
ferent phase IIa trials (see below) have indicated  a good 
safety profile for vafidemstat even after long-term exposure 
(up to 18 months).
The dose range chosen in this clinical trial was the 
human equivalent of the dose range used in efficacy stud-
ies in rodent models. In rodents, vafidemstat showed good 
brain penetration and TE in brain and peripheric tissues and 
provided a 30-fold window between the therapeutic effect 
and hematopoietic impact. Importantly, in rodents, efficacy 
could be obtained at doses with no or negligible hematopoi-
etic engagement. Based on the data obtained in this study 
and the characterization of platelet dynamics, phase II doses 
were established at 0.6 and 1.2 mg/day. These doses were 
estimated to be sufficient to reach ~ 60–80% KDM1A TE 
(efficacious in preclinical species) while avoiding a clinically 
relevant platelet impact, based on the exposure–response 
relationships (half and 80% maximal effective concentra-
tion). Evaluation of long-term data in phase IIa trials will 
permit vafidemstat dose selection for future pivotal phase 
III studies.
5  Conclusion
The 5-day treatment with vafidemstat was safe in the origi-
nally designed dose range. The pharmacodynamic results 
confirmed dose-dependent KDM1A TE but the absence 
of any significant MAOB inhibition at the doses used and 
confirmed the CNS penetration of vafidemstat. This phase I 
trial permitted the characterization of platelet dynamics and 
selection of phase IIa doses.
Vafidemstat has been tested in several phase IIa trials in 
patients with relapsing–remitting and secondary-progressive 
MS, in patients with mild to moderate Alzheimer’s disease, 
and in patients displaying aggression in different psychi-
atric diseases and moderate to severe Alzheimer’s disease 
(EUDRACT 2017-002838-23; 2017-004893-32; 2018-
002140-88; 2019-001436-54; NCT03867253). Based on the 
good safety profile in older adults in long-term treatments, 
and on the rapid and potent anti-inflammatory properties 
observed in models for MS, a randomized, open-label phase 
II study is ongoing to evaluate the ability of vafidemstat 
to prevent acute respiratory distress syndrome in severely 
ill adult patients with severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2; coronavirus disease 2019) 
(EUDRACT Nº 2020-001618-39). Recent phase IIa efficacy 
data support vafidemstat as an emerging therapeutic option 
for treatment of agitation/aggression in psychiatric disor-
ders such as attention-deficit/hyperactivity disorder, border-
line personality disorder (BPD), autism spectrum disorder, 
and moderate-severe Alzheimer’s disease [22, 23]. Based 
on these results, a multicenter, double-blind, randomized, 
placebo-controlled phase IIb trial to evaluate the efficacy and 
safety of vafidemstat in patients with BPD with agitation/
aggressiveness has been initiated (PORTICO; EUDRACT 
Nº 2020-003469-20), and an additional phase IIb trial to 
address cognitive impairment and negative symptoms in 
patients with schizophrenia is planned to launch in 2021.
 R. M. Antonijoan et al.
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